Plexision, a biotechnology company, recently secured a $365,000 investment from the Richard King Mellon Foundation. This funding aims to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision’s cell-based blood tests. Consequently, this will significantly improve predictive accuracy for complex transplant outcomes.
The investment specifically enhances Plexision's platform, enabling it to rank and predict the likelihood of multiple outcomes for each patient. This advancement transforms how clinicians interpret immunologic signals, moving beyond simple binary results. Furthermore, it supports the delivery of precision medicine in transplant care.
Plexision's proprietary technology delivers test results rapidly, often within 6 to 24 hours. This speed allows for timely intervention in managing immunosuppressive drugs. Unlike traditional diagnostic providers such as Quest Diagnostics or LabCorp, Plexision focuses on detailed immune status.
The company's blood tests predict common rejection subtypes and post-transplant infections using a unified immune cell function platform. Integrating machine learning with these tests ranks risks across various outcome categories. For example, the PlexABMR test accurately predicted antibody-mediated rejection in kidney transplant recipients.
Advancing Transplant Diagnostics with AI
These advanced capabilities have undergone validation in multi-center studies. Plexision plans to report these findings at the World Transplant Congress in San Francisco during August 2025. This ongoing research solidifies the company's position in specialized diagnostics.
Plexision's CLIA-approved and CAP-accredited reference laboratory in Pittsburgh, PA, performs all tests. Blood samples ship in from clinical partners for analysis.
